External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involv
![An integrated nomogram combining deep learning, Prostate Imaging–Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study - The An integrated nomogram combining deep learning, Prostate Imaging–Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study - The](https://www.thelancet.com/cms/asset/a58b2e05-56ce-4538-aefa-b0f74c2aada3/gr1.jpg)
An integrated nomogram combining deep learning, Prostate Imaging–Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study - The
![Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK](https://talkaboutprostatecancer.wordpress.com/files/2009/12/mskcc-image-c.jpg)
Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK
![Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy - ScienceDirect Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1078143919303242-gr1.jpg)
Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy - ScienceDirect
![Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer - eBioMedicine Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer - eBioMedicine](https://www.thelancet.com/cms/attachment/751f1829-7219-4c49-8ff5-bf6559216354/gr1_lrg.jpg)
Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer - eBioMedicine
![External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging - Soeterik - External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging - Soeterik -](https://bjui-journals.onlinelibrary.wiley.com/cms/asset/702eb4af-ba4c-45fa-bf34-dd7f2d2bd623/bju15376-fig-0003-m.jpg)
External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging - Soeterik -
![External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging - Soeterik - External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging - Soeterik -](https://bjui-journals.onlinelibrary.wiley.com/cms/asset/9d5ee1fb-33f1-48da-924c-36a2e1471e12/bju15376-fig-0002-m.jpg)
External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging - Soeterik -
![Prostate Cancer (Part 1): Introduction to Low & Favorable-Intermediate Risk Prostate Cancer - YouTube Prostate Cancer (Part 1): Introduction to Low & Favorable-Intermediate Risk Prostate Cancer - YouTube](https://i.ytimg.com/vi/bNV4IddiHu8/maxresdefault.jpg)
Prostate Cancer (Part 1): Introduction to Low & Favorable-Intermediate Risk Prostate Cancer - YouTube
![Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and Implications for Risk Stratification: A Systematic Review - European Urology Focus Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and Implications for Risk Stratification: A Systematic Review - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/6b63e50b-1d4a-45fa-874f-7ebf3b36f232/gr1_lrg.jpg)
Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and Implications for Risk Stratification: A Systematic Review - European Urology Focus
![Active Surveillance of Prostate Cancer: Advances for More-Accurate Risk Assessment | Memorial Sloan Kettering Cancer Center Active Surveillance of Prostate Cancer: Advances for More-Accurate Risk Assessment | Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/sites/default/files/styles/large/public/node/146245/3x2/prostate_article.jpeg)
Active Surveillance of Prostate Cancer: Advances for More-Accurate Risk Assessment | Memorial Sloan Kettering Cancer Center
![PDF) External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer PDF) External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer](https://www.researchgate.net/profile/Zilvinas-Venclovas-2/publication/340504409/figure/fig3/AS:878025453338630@1586348989541/Decision-curve-analysis-demonstrating-the-net-benefit-associated-with-the-use-of-Memorial_Q320.jpg)
PDF) External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer
![PDF) External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer PDF) External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer](https://i1.rgstatic.net/publication/340504409_External_validation_of_Memorial_Sloan_Kettering_Cancer_Center_nomogram_and_prediction_of_optimal_candidate_for_lymph_node_dissection_in_clinically_localized_prostate_cancer/links/5e8dc3b6299bf1307985f84a/largepreview.png)
PDF) External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer
![Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK](https://talkaboutprostatecancer.files.wordpress.com/2009/12/mskcc-image-d.jpg?w=584)
Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK
![Epigenetic loss of heterogeneity from low to high grade localized prostate tumours | Nature Communications Epigenetic loss of heterogeneity from low to high grade localized prostate tumours | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-27615-8/MediaObjects/41467_2021_27615_Fig1_HTML.png)
Epigenetic loss of heterogeneity from low to high grade localized prostate tumours | Nature Communications
![Improving Disease Prognostics - Cambridge Prostate Cancer - facilitating world class research, diagnostics and care Improving Disease Prognostics - Cambridge Prostate Cancer - facilitating world class research, diagnostics and care](https://cambridgeprostatecancer.com/wp-content/uploads/cam1-min-768x431.jpg)
Improving Disease Prognostics - Cambridge Prostate Cancer - facilitating world class research, diagnostics and care
![Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial - | SpringerLink Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial - | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00259-020-04974-w/MediaObjects/259_2020_4974_Fig5_HTML.jpg)
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial - | SpringerLink
![Analysis of outcome for DESNT cancers identified by random forest (RF)... | Download Scientific Diagram Analysis of outcome for DESNT cancers identified by random forest (RF)... | Download Scientific Diagram](https://www.researchgate.net/publication/316374993/figure/fig3/AS:681977824940033@1539607592361/Analysis-of-outcome-for-DESNT-cancers-identified-by-random-forest-RF-classification.jpg)
Analysis of outcome for DESNT cancers identified by random forest (RF)... | Download Scientific Diagram
![Stratification of prostate cancer samples based on the percentage of... | Download Scientific Diagram Stratification of prostate cancer samples based on the percentage of... | Download Scientific Diagram](https://www.researchgate.net/publication/340060811/figure/fig1/AS:871285701763072@1584742107562/Stratification-of-prostate-cancer-samples-based-on-the-percentage-of-DESNT-cancer.png)